ClinicalTrials.gg
RecruitingNCT05451004SELECTUpdated Jul 14, 2026

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

A Phase 3 interventional study of Lymphatic Mapping with SPECT-CT and Ipsilateral and Contralateral Neck in Oropharyngeal Cancer, sponsored by Canadian Cancer Trials Group. Recruiting at 38 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.

Sponsored by Canadian Cancer Trials Group · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 235 studies in Oropharyngeal Neoplasms with a site in United States — 63 open to participants now, 98 under way, 11 of them phase 3. Oropharyngeal Neoplasms · United States.

Planned enrollment
10th of 189
510 · median 42
Started
2023
with 14 others
Phase 3
14 of 235
3 open now
Primary completion
2030-08
later than 86 of 97 live
Registered
179th of 235
by date

Among the 235 studies in Oropharyngeal Neoplasms with a site in United States, this one is the 10th largest by planned enrollment of the 189 interventional ones that give a count, is one of 15 that started in 2023, is one of 14 in phase 3, reaches primary completion later than 86 of the 97 other live ones, and was the 179th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

63 of the 235 studies in Oropharyngeal Neoplasms with a site in United States are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 235 studies in Oropharyngeal Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is being done to answer the following question:

Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?

Read the detailed description

This study is being conducted in order to find out if this approach is as good as the usual approach in controlling the cancer and has fewer side effects and better quality of life. The usual approach for patients who are not in a study is treatment which includes radiotherapy to the tumour and to both sides of the neck to decrease the risk of spread or recurrence of the cancer

03

Conditions studied

  • Oropharyngeal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with proven diagnosis of lateralized OPC (tonsil, tongue base, soft palate, or pharyngeal wall) not involving or crossing midline.
  • HPV positive or negative (by p16 immunohistochemistry).
  • Clinical stage T1-3 M0 (UICC/AJCC TNM 8th Edition). Nodal involvement may include no nodes or single or multiple ipsilateral lymph nodes (largest ≤6cm in maximum diameter)
  • Radiological investigations within 8 weeks of registration:

    • CT or MRI of the neck (with head imaging as indicated);
    • PET-CT scan
    • Chest CT scan
  • Planned definitive RT or CRT with bilateral neck RT (patients planned for unilateral neck RT are excluded).
  • Intent to deliver concurrent chemotherapy or not must be known at the time of randomization. As this is a pragmatic trial, even patients who are not candidates for systemic therapy will be eligible for participation.
  • (ECOG) performance status of 0, 1, or 2.
  • Willing to complete the quality of life and/or health utility questionnaire, if sufficiently fluent in available language(s).
  • prior to registration
  • Accessible for treatment and follow-up.
  • Commencement of definitive RT within 28 days (+ 14 days) of randomization.
  • Injection procedure for lymphatic mapping may be performed in the nuclear medicine, ambulatory clinic, or operating room setting
  • Women/men of must have agreed to use a highly effective method
  • Patients with a prior or concurrent whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the regimen are eligible for this trial.
  • Patient must consent to provision of, and investigator(s) must confirm location and commitment to obtain a representation of formalin fixed paraffin block of non-cytology tumour tissue in order that the specific correlative marker assays

Exclusion criteria

Exclusion Criteria:

  • T1-T2 cancers isolated to the tonsil fossa (i.e. without any soft palate, tongue base, posterior pharyngeal wall or posterior tonsil pillar involvement) with no involved lymph nodes or with a single ipsilateral node \< 3 cm without extranodal extension.
  • Tonsil or tongue base primary cancer who have previously undergone diagnostic palatine or lingual tonsillectomy with either complete excision or with no clinically apparent residual disease
  • Previous head and neck cancer or multiple synchronous primary head and neck cancers
  • Previous induction or chemotherapy.
  • Previous radiation therapy to the head and neck or comprehensive neck dissection of at least 3 levels on either side (due to potential for disrupted lymphatic channels and drainage pathways). Patients who have had excisional of involved lymph nodes are eligible
  • Radiotracer allergy
  • Severe, active co-morbidity including any of the following:

    • or other pulmonary illness requiring hospitalization within 30 days of registration
    • Unstable angina and/or congestive heart failure requiring hospitalization within the 30 days of registration
    • Acute myocardial infarction within 30 days of study registration
    • Diseases precluding RT (e.g. scleroderma)
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
510 participants (estimated)

Study arms

  • Experimental
    Lympathic Mapping with SPECT-CT guided Radiotherapy

    Other: Lymphatic Mapping with SPECT-CT

  • Active comparator
    Bilateral Neck Radiotherapy

    Radiation: Ipsilateral and Contralateral Neck

Interventions

  • OtherLymphatic Mapping with SPECT-CT

    Radiation: Ipsilateral Neck Radiotherapy and SPECT-CT Guided Contralateral Neck Radiotherapy

  • RadiationIpsilateral and Contralateral Neck

    Radiotherapy

06

What researchers measure

Primary outcomes

  1. Disease-free Survival

    Time frame: 8 years

Secondary outcomes

  1. Quality of Life using M.D. Anderson Dysphagia Inventory (MDADI)

    Possible range of scores between 0 and 100 (higher scores indicating better swallowing and lower score indicating poor swallowing).

    Time frame: 8 years

  2. Xerostomia-related Quality of Life using Xerostomia Questionnaire (XQ)

    Clinically meaningful worsening of xerostomia (10 units on XQ) from baseline to 12 months post RT

    Time frame: 8 years

  3. Isolated contralateral neck failure (iCNF)

    Time frame: 8 years

  4. Overall Survival (OS)

    Time frame: 8 years

  5. Logo-regional Failure (LRF)

    Time frame: 8 years

  6. Distant Metastases (DM)

    Time frame: 8 years

  7. Incidence and Severity of Radiation-related Toxicities

    Time frame: 8 years

  8. Patient-Reported Toxicities using PRO CTCAE

    Time frame: 8 years

  9. Gastrostomy Tube Usage

    Time frame: 8 years

  10. Resource Utilization

    Time frame: 8 years

  11. Lost Productivity

    Healthcare system and societal resources will be quantified over the course of the trial to generate utilization information by patient in each study arm. We will generate an average cost per study subject by treatment arm for an overall mean cost per study arm

    Time frame: 8 years

  12. Financial Toxicity [Financial Index of Toxicity (FIT)]

    Time frame: 8 years

  13. Health Utilities using EQ-5D

    Time frame: 8 years

07

Study locations

30 of 38 sites recruiting
08

References and documents

Publications

  • Gau M, Alfaraj FA, Huang SH, O'Sullivan B, Su J, Xu W, Hamilton SN, Maletta A, Salman O, McInerney M, Javed A, Sanz-Garcia E, Bratman S, Hahn E, Hope A, Kim JJ, Malik N, McPartlin A, Tsai CJ, Waldron J, Yao CMKL, de Almeida JR, Hosni A. Unilateral vs bilateral neck irradiation: The importance of careful patient selection in tailoring radiation therapy for lateralized palatine-tonsil and non-palatine-tonsil oropharyngeal carcinoma. Radiother Oncol. 2025 Sep;210:111049. doi: 10.1016/j.radonc.2025.111049. Epub 2025 Jul 19. PubMed 40692081 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2023 (actual). Primary completion is estimated for Aug 2030, 90 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2022
First posted
Jul 11, 2022
StartActual
Feb 10, 2023
Primary completionEst.
Aug 30, 2030
CompletionEst.
Aug 30, 2031
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05451004
Lead sponsor
Canadian Cancer Trials Group
Responsible party
Sponsor
First posted
Jul 11, 2022
Start date
Feb 10, 2023
Primary completion
Aug 30, 2030 (estimated)
Completion
Aug 30, 2031 (estimated)
Last update
Jul 14, 2026

Study contacts

Wendy Parulekar
Contact
wparulekar@ctg.queensu.ca
613-533-6430
John R de Almeida
study chair · University Health Network, Princess Margaret Hospital, Toronto ON Canada
Ali Hosni
study chair · University Health Network, Princess Margaret Hospital, Toronto ON Canada

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion